Major French study confirms non-inferiority of Avastin versus Lucentis
A multicentre French study comparing bevacizumab (Avastin, Genentech) and ranibizumab (Lucentis, Genentech) found that both drugs were comparable in terms of clinical efficacy for the treatment of neovascular age-related macular degeneration (AMD).
Presenting the results of the Group d’Evaluation Français Avastin versus Lucentis (GEFAL) study at the 13th EURETINA Congress, Laurent Kodjikian MD of the University Hospital of Lyon, said that the outcomes are in line with those of the Comparison of AMD Treatment Trial (CATT) published in 2012.
The GEFAL study was a prospective, double-masked, randomised study conducted in 38 public and private-sector French ophthalmology centres from June 2009 to November 2011.
Tags: intraocular pressure, optic nerve
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.